Sobi支付27 500万美元,将阿斯帕维利版税削减90%,为欧盟的罕见肾病批准提供资金。 Sobi pays $275M to cut Aspaveli royalties by 90%, funding rare kidney disease approvals in EU.

Sobi和Apellis制药公司修订了对Aspaveli的许可证协议,将Sobi的前美国特许使用费义务削减90%,以换取2.75亿美元的预付付款和高达2 500万美元的里程碑付款。 Sobi and Apellis Pharmaceuticals have amended their licensing agreement for Aspaveli, reducing Sobi's ex-US royalty obligations by 90% in exchange for a $275 million upfront payment and up to $25 million in milestone payments. 这笔交易资金用于欧盟对罕见肾病C3G和IC-MPGN的监管核准。 The deal funds regulatory approvals in the EU for rare kidney diseases C3G and IC-MPGN. Aspaveli已经获得欧盟和美国批准,用于治疗PNH,目前正在对新迹象进行审查。 Aspaveli is already approved in the EU and US for treating PNH, with reviews ongoing for the new indications.